Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$143.68 +0.3%	$134.26	$110.04 ▼ $204.18	$21.07B	0.11	1.56 million shs	1.94 million shs
INCY Incyte	$83.90 +0.9%	$78.86	$53.56 ▼ $87.99	$16.38B	0.75	1.86 million shs	1.69 million shs
MDGL Madrigal Pharmaceuticals	$427.05 +0.3%	$366.84	$200.63 ▼ $457.16	$9.48B	-1.02	377,399 shs	243,387 shs
NBIX Neurocrine Biosciences	$140.90 +0.3%	$134.38	$84.23 ▼ $154.61	$13.97B	0.28	1.21 million shs	780,536 shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	-1.06%	+1.39%	+3.41%	+13.24%	-26.74%
INCY Incyte	+0.05%	-3.95%	-4.35%	+20.83%	+30.81%
MDGL Madrigal Pharmaceuticals	-1.53%	-6.21%	+15.08%	+52.22%	+76.01%
NBIX Neurocrine Biosciences	-1.01%	-2.34%	+5.67%	+12.46%	+14.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$143.68 +0.3%	$134.26	$110.04 ▼ $204.18	$21.07B	0.11	1.56 million shs	1.94 million shs
INCY Incyte	$83.90 +0.9%	$78.86	$53.56 ▼ $87.99	$16.38B	0.75	1.86 million shs	1.69 million shs
MDGL Madrigal Pharmaceuticals	$427.05 +0.3%	$366.84	$200.63 ▼ $457.16	$9.48B	-1.02	377,399 shs	243,387 shs
NBIX Neurocrine Biosciences	$140.90 +0.3%	$134.38	$84.23 ▼ $154.61	$13.97B	0.28	1.21 million shs	780,536 shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	-1.06%	+1.39%	+3.41%	+13.24%	-26.74%
INCY Incyte	+0.05%	-3.95%	-4.35%	+20.83%	+30.81%
MDGL Madrigal Pharmaceuticals	-1.53%	-6.21%	+15.08%	+52.22%	+76.01%
NBIX Neurocrine Biosciences	-1.01%	-2.34%	+5.67%	+12.46%	+14.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.32	Hold	$181.65	26.43% Upside
INCY Incyte	2.33	Hold	$82.53	-1.63% Downside
MDGL Madrigal Pharmaceuticals	2.90	Moderate Buy	$483.38	13.19% Upside
NBIX Neurocrine Biosciences	2.85	Moderate Buy	$160.26	13.74% Upside

Current Analyst Ratings Breakdown

Latest MDGL, BIIB, INCY, and NBIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$115.00 ➝ $118.00
9/12/2025	MDGL Madrigal Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$428.00 ➝ $526.00
9/5/2025	NBIX Neurocrine Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$144.00 ➝ $149.00
9/5/2025	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$158.00 ➝ $163.00
9/4/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/4/2025	INCY Incyte	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$90.00 ➝ $104.00
9/4/2025	MDGL Madrigal Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$500.00
8/26/2025	MDGL Madrigal Pharmaceuticals	Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2025	MDGL Madrigal Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$390.00 ➝ $554.00
8/22/2025	INCY Incyte	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$67.00 ➝ $73.00
8/20/2025	MDGL Madrigal Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$483.00 ➝ $485.00

(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.68B	2.18	$22.92 per share	6.27	$114.71 per share	1.25
INCY Incyte	$4.58B	3.57	$0.56 per share	150.11	$17.90 per share	4.69
MDGL Madrigal Pharmaceuticals	$180.13M	52.63	N/A	N/A	$34.59 per share	12.35
NBIX Neurocrine Biosciences	$2.36B	5.93	$3.36 per share	41.97	$25.58 per share	5.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.46	13.74	8.70	1.14	15.31%	13.85%	8.32%	10/29/2025 (Estimated)
INCY Incyte	$32.62M	$4.40	19.07	12.83	0.65	18.99%	21.99%	14.43%	11/4/2025 (Estimated)
MDGL Madrigal Pharmaceuticals	-$465.89M	-$12.85	N/A	N/A	N/A	-54.68%	-38.38%	-27.32%	10/30/2025 (Estimated)
NBIX Neurocrine Biosciences	$341.30M	$3.38	41.69	21.78	1.02	13.88%	13.22%	9.39%	10/29/2025 (Estimated)

Latest MDGL, BIIB, INCY, and NBIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	MDGL Madrigal Pharmaceuticals	-$3.48	-$1.90	+$1.58	-$1.90	$158.94 million	$212.80 million
7/31/2025	Q2 2025	BIIB Biogen	$3.93	$5.47	+$1.54	$4.33	$2.32 billion	$2.65 billion
7/30/2025	Q2 2025	NBIX Neurocrine Biosciences	$0.98	$1.06	+$0.08	$1.06	$653.09 million	$687.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.36	2.50	1.79
INCY Incyte	0.01	2.85	2.78
MDGL Madrigal Pharmaceuticals	0.17	5.11	4.78
NBIX Neurocrine Biosciences	N/A	3.20	3.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
INCY Incyte	96.97%
MDGL Madrigal Pharmaceuticals	98.50%
NBIX Neurocrine Biosciences	92.59%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.18%
INCY Incyte	17.80%
MDGL Madrigal Pharmaceuticals	21.50%
NBIX Neurocrine Biosciences	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	7,605	146.62 million	146.35 million	Optionable
INCY Incyte	2,617	195.28 million	160.52 million	Optionable
MDGL Madrigal Pharmaceuticals	90	22.20 million	17.43 million	Optionable
NBIX Neurocrine Biosciences	1,800	99.18 million	94.92 million	Optionable

MDGL, BIIB, INCY, and NBIX Headlines

Recent News About These Companies

Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025

3 hours ago | prnewswire.com

Juncture Wealth Strategies LLC Sells 2,766 Shares of Neurocrine Biosciences, Inc. $NBIX

September 16 at 7:27 AM | marketbeat.com

City Center Advisors LLC Buys New Stake in Neurocrine Biosciences, Inc. $NBIX

September 16 at 4:35 AM | marketbeat.com

Neurocrine Biosciences, Inc. $NBIX Holdings Cut by First Hawaiian Bank

September 16 at 3:58 AM | marketbeat.com

Swedbank AB Raises Stock Position in Neurocrine Biosciences, Inc. $NBIX

September 15 at 5:27 AM | marketbeat.com

Intech Investment Management LLC Has $3.96 Million Stake in Neurocrine Biosciences, Inc. $NBIX

September 15 at 4:31 AM | marketbeat.com

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Boosts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

September 15 at 4:07 AM | marketbeat.com

Integrated Wealth Concepts LLC Buys 4,526 Shares of Neurocrine Biosciences, Inc. $NBIX

September 15 at 3:19 AM | marketbeat.com

Plato Investment Management Ltd Has $255,000 Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

September 14 at 4:28 AM | marketbeat.com

Woodline Partners LP Invests $14.70 Million in Neurocrine Biosciences, Inc. $NBIX

September 13 at 4:37 AM | marketbeat.com

Great Lakes Advisors LLC Has $3.54 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX

September 13 at 4:19 AM | marketbeat.com

Vident Advisory LLC Invests $202,000 in Neurocrine Biosciences, Inc. $NBIX

September 13 at 3:13 AM | marketbeat.com

United Services Automobile Association Makes New $741,000 Investment in Neurocrine Biosciences, Inc. $NBIX

September 11, 2025 | marketbeat.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Short Interest Up 39.6% in August

September 10, 2025 | marketbeat.com

Teza Capital Management LLC Sells 12,560 Shares of Neurocrine Biosciences, Inc. $NBIX

September 10, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Acquires 21,726 Shares of Neurocrine Biosciences, Inc. $NBIX

September 10, 2025 | marketbeat.com

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Amundi

September 10, 2025 | marketbeat.com

Neurocrine Biosciences, Inc. (NBIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

September 9, 2025 | seekingalpha.com

Parkman Healthcare Partners LLC Has $18.62 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX

September 8, 2025 | marketbeat.com

Neurocrine Biosciences, Inc. $NBIX Shares Sold by EFG Asset Management North America Corp.

September 7, 2025 | marketbeat.com

AQR Capital Management LLC Sells 822,261 Shares of Neurocrine Biosciences, Inc. $NBIX

September 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MDGL, BIIB, INCY, and NBIX Company Descriptions

Biogen NASDAQ:BIIB

$143.68 +0.36 (+0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$143.55 -0.13 (-0.09%)

As of 06:04 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$83.90 +0.76 (+0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$83.68 -0.22 (-0.26%)

As of 04:59 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Madrigal Pharmaceuticals NASDAQ:MDGL

$427.05 +1.45 (+0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$426.39 -0.66 (-0.15%)

As of 04:49 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Neurocrine Biosciences NASDAQ:NBIX

$140.90 +0.46 (+0.33%)

Closing price 04:00 PM Eastern

Extended Trading

$141.90 +1.01 (+0.71%)

As of 05:02 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDGL, BIIB, INCY, and NBIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDGL, BIIB, INCY, and NBIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDGL, BIIB, INCY, and NBIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDGL, BIIB, INCY, and NBIX Company Descriptions

Biogen NASDAQ:BIIB

Incyte NASDAQ:INCY

Madrigal Pharmaceuticals NASDAQ:MDGL

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDGL, BIIB, INCY, and NBIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDGL, BIIB, INCY, and NBIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDGL, BIIB, INCY, and NBIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDGL, BIIB, INCY, and NBIX Company Descriptions

Biogen NASDAQ:BIIB

Incyte NASDAQ:INCY

Madrigal Pharmaceuticals NASDAQ:MDGL

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools